Renal Involvement in COVID-19: A Review of the Literature

References

• World Health Organisation. Novel coronavirus – China; 2020. Available from: https://coronavirus.jhu.edu/map.html.
   Google Scholar
• Russo A, Minichini C, Starace M, et al. Current status of laboratory diagnosis for covid-19: a narrative review. Infect Drug Resist. 2020;Volume 13:2657–2665. doi:10.2147/IDR.S264020
   Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi:10.1016/S0140-6736(20)30566-332171076
   PubMed Web of Science ®Google Scholar
• Macera M, De Angelis G, Sagnelli C, Coppola N. Clinical presentation of covid-19: case series and review of the literature. Int J Environ Res Public Health. 2020;17(14):5062. doi:10.3390/ijerph17145062
   Web of Science ®Google Scholar
• Carfora V, Spiniello G, Ricciolino R, et al. Anticoagulant treatment in COVID-19: a narrative review. J Thromb Thrombolysis. 2020. doi:10.1007/s11239-020-02242-0
   PubMed Web of Science ®Google Scholar
• Mottola FF, Verde N, Ricciolino R, et al. Cardiovascular system in COVID-19: simply a viewer or a leading actor? Life (Basel, Switzerland). 2020;10(9):165.
   Web of Science ®Google Scholar
• Cheng Y, Luo R, Wang K, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–838. doi:10.1016/j.kint.2020.03.00532247631
   PubMed Web of Science ®Google Scholar
• Ali H, Daoud A, Mohamed MM, et al. Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. Ren Fail. 2020;42(1):393–397. doi:10.1080/0886022X.2020.1756323.32340507
   PubMed Web of Science ®Google Scholar
• Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. JAMA. 2020;323(16):1612. doi:10.1001/jama.2020.432632191259
   PubMed Web of Science ®Google Scholar
• Chan L, Chaudhary K, Saha A, et al. Acute kidney injury in hospitalized patients with COVID-19. medRxiv [Preprint]. 2020;32(1):151–160. doi:10.1101/2020.05.04.20090944.
   Google Scholar
• Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–513. doi:10.1016/S0140-6736(20)30211-732007143
   PubMed Web of Science ®Google Scholar
• Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020;368:m1091. doi:10.1136/bmj.m109132217556
   PubMed Web of Science ®Google Scholar
• Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720. doi:10.1056/NEJMoa200203232109013
   PubMed Web of Science ®Google Scholar
• Hirsch JS, Ng JH, Ross DW, et al., Northwell COVID-19 Research Consortium; Northwell Nephrology COVID-19 Research Consortium. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020;98(1):209–218. doi:10.1016/j.kint.2020.05.006.32416116
   PubMed Web of Science ®Google Scholar
• Wang HE, Muntner P, Chertow GM, Warnock DG. Acute kidney injury and mortality in hospitalized patients. Am J Nephrol. 2012;35(4):349–355. doi:10.1159/000337487.22473149
   PubMed Web of Science ®Google Scholar
• Shen X, Fu L, Fei J, et al. Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis. medRxiv. 2020. doi:10.1101/2020.03.24.20042408
   Google Scholar
• Yan Q, Zuo P, Cheng L, et al. Acute kidney injury is associated with in-hospital mortality in older patients with COVID-19. J Gerontol a Biol Sci Med Sci. 2020;glaa181. doi:10.1093/gerona/glaa181.
   Web of Science ®Google Scholar
• Zhang G, Hu C, Luo L, et al. Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020;127:104364. doi:10.1016/j.jcv.2020.10436432311650
   PubMed Web of Science ®Google Scholar
• Yang L, Xing G, Wang L, et al. Acute kidney injury in China: a cross-sectional survey. Lancet. 2015;386(10002):1465–1471. doi:10.1016/S0140-6736(15)00344-X26466051
   PubMed Web of Science ®Google Scholar
• Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179–84. doi:10.1159/00033978922890468
   PubMedGoogle Scholar
• Robbins-Juarez SY, Qian L, King KL, et al. Outcomes for patients with COVID-19 and acute kidney injury: a systematic review and meta-analysis. Kidney Int Rep. 2020;5(8):1149–1160. doi:10.1016/j.ekir.2020.06.01332775814
   PubMed Web of Science ®Google Scholar
• Pei G, Zhang Z, Peng J, et al. Renal involvement and early prognosis in patients with COVID-19 pneumonia. J Am Soc Nephrol. 2020;31(6):1157–116532345702
   PubMed Web of Science ®Google Scholar
• Joannidis M, Forni LG, Klein SJ, et al. Lung–kidney interactions in critically ill patients: consensus report of the Acute Disease Quality Initiative (ADQI) 21 workgroup. Intensive Care Med. 2020;46(4):654–672. doi:10.1007/s00134-019-05869-731820034
   PubMed Web of Science ®Google Scholar
• Serfozo P, Wysocki J, Gulua G, et al. Ang II (Angiotensin II) conversion to Angiotensin-(1–7) in the circulation is POP (Prolyloligopeptidase)-dependent and ACE2 (Angiotensin-Converting Enzyme 2)-independent. Hypertension. 2020;75(1):173–182. doi:10.1161/HYPERTENSIONAHA.119.1407131786979
   PubMed Web of Science ®Google Scholar
• Ye M, Wysocki J, William J, et al. Glomerular localization and expression of angiotensin-converting enzyme 2 and angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol. 2006;17(11):3067–3075. doi:10.1681/ASN.200605042317021266
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605–2610. doi:10.1161/CIRCULATIONAHA.104.51046115897343
   PubMed Web of Science ®Google Scholar
• South AM, Diz DI, Chappell MC. COVID-19, ACE2, and the cardiovascular consequences. Am J Physiol Heart Circ Physiol. 2020;318(5):H1084–H1090. doi:10.1152/ajpheart.00217.202032228252
   PubMed Web of Science ®Google Scholar
• Chappell MC, Marshall AC, Alzayadneh EM, Shaltout HA, Diz DI. Update on the angiotensin converting enzyme 2-angiotensin (1–7)-Mas receptor axis: fetal programing, sex differences, and intracellular pathways. Front Endocrinol (Lausanne). 2014;5:1–13. doi:10.3389/fendo.2014.0000124474947
   PubMed Web of Science ®Google Scholar
• Su H, Yang M, Wan C, et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020;98(1):219–227. doi:10.1016/j.kint.2020.04.00332327202
   PubMed Web of Science ®Google Scholar
• Puelles VG, Lütgehetmann M, Lindenmeyer MT, et al. Multiorgan and renal tropism of SARS-CoV-2. N Engl J Med. 2020;383(6):590–592. doi:10.1056/NEJMc201140032402155
   PubMed Web of Science ®Google Scholar
• Batlle D, Soler MJ, Sparks MA, et al. Acute kidney injury in COVID-19: emerging evidence of a distinct pathophysiology. J Am Soc Nephrol. 2020;31(7):1380–1383. doi:10.1681/ASN.202004041932366514
   PubMed Web of Science ®Google Scholar
• Mizuiri S, Hemmi H, Arita M, et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. Am J Kidney Dis. 2008;51(4):613–623. doi:10.1053/j.ajkd.2007.11.02218371537
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Hilbrands LB. CKD is a key risk factor for COVID-19 mortality. Nat Rev Nephrol. 2020;16(12):705–706. doi:10.1038/s41581-020-00349-4.32848205
   PubMed Web of Science ®Google Scholar
• Ronco C, Reis T. Kidney involvement in COVID-19 and rationale for extracorporeal therapies. Nat Rev Nephrol. 2020;16(1):1–3. doi:10.1038/s41581-019-0226-431654043
   PubMed Web of Science ®Google Scholar
• Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517–528. doi:10.1007/s00281-017-0639-828555385
   PubMed Web of Science ®Google Scholar
• Libby P, Simon DI. Inflammation and thrombosis: the clot thickens. Circulation. 2001;103(13):1718–1720. doi:10.1161/01.CIR.103.13.171811282900
   PubMed Web of Science ®Google Scholar
• Tian S, Hu W, Niu L, et al. Pulmonary pathology of early-phase 2019 novel coronavirus (COVID-19) pneumonia in two patients with lung cancer. J Thorac Oncol. 2020;15(5):700–704. doi:10.1016/j.jtho.2020.02.01032114094
   PubMed Web of Science ®Google Scholar
• Huang X. Chinese society of neurology, Peripheral neuropathy collaboration group of Chinese Society of Neurology, Chinese society of electromyography & Chinese society of neuromuscular disease. Chinese expert consensus on diagnosis and treatment of subacute combined degeneration. Chinese J Neurol. 2020;53:269–273.
   Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934. doi:10.1001/jamainternmed.2020.099432167524
   PubMed Web of Science ®Google Scholar
• Husain-Syed F, Slutsky AS, Ronco C. Lung-kidney cross-talk in the critically ill patient. Am J Respir Crit Care Med. 2016;194(4):402–414. doi:10.1164/rccm.201602-0420CP27337068
   PubMed Web of Science ®Google Scholar
• Zhang C, Wu Z, Li JW, Zhao H, Wang GQ. The cytokine release syndrome (CRS) of severe COVID-19 and interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality. Int J Antimicrob Agents. 2020;55(5):105954. doi:10.1016/j.ijantimicag.2020.10595432234467
   PubMed Web of Science ®Google Scholar
• Della-Torre E, Campochiaro C, Cavalli G, et al., SARI-RAF Study Group; SARI-RAF Study Group members. Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Ann Rheum Dis. 2020;79(10):1277–1285. doi:10.1136/annrheumdis-2020-218122.32620597
   PubMed Web of Science ®Google Scholar
• Benucci M, Giannasi G, Cecchini P, et al. COVID-19 pneumonia treated with Sarilumab: a clinical series of eight patients. J Med Virol. 2020;92(11):2368–2370. doi:10.1002/jmv.2606232472703
   PubMed Web of Science ®Google Scholar
• Khamis F, Al-Zakwani I, Hashmi SA, et al. Therapeutic plasma exchange in adults with severe COVID-19 infection. Int J Infect Dis. 2020;99:214–218. doi:10.1016/j.ijid.2020.06.064.32585284
   PubMed Web of Science ®Google Scholar
• Azzi Y, Parides M, Alani O, et al. COVID-19 infection in kidney transplant recipients at the epicenter of pandemics [published online ahead of print, 2020 Oct 16]. Kidney Int. 2020;98(6):1559–1567. doi:10.1016/j.kint.2020.10.00433069762
   PubMed Web of Science ®Google Scholar
• Cavagna L, Seminari E, Zanframundo G, et al. Calcineurin inhibitor-based immunosuppression and COVID-19: results from a multidisciplinary cohort of patients in Northern Italy. Microorganisms. 2020;8(7):977. doi:10.3390/microorganisms8070977.
   Web of Science ®Google Scholar
• Gralinski LE, Sheahan TP, Morrison TE, et al. Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. MBio. 2018;9(5). doi:10.1128/mBio.01753-18
   PubMed Web of Science ®Google Scholar
• Jiang Y, Zhao G, Song N, et al. Blockade of the C5a–C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018;7(1):1–12. doi:10.1038/s41426-018-0063-829323102
   PubMed Web of Science ®Google Scholar
• Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040–4047. doi:10.26355/eurrev_202004_2087532329881
   PubMed Web of Science ®Google Scholar
• Pitts TC.Eculizumab (Soliris) in covid-19 infected patients. Case Med Res. 2020. doi:10.31525/ct1-nct4288713
   Google Scholar
• Yang B, Fulcher JA, Ahn J, et al. Clinical Characteristics and Outcomes of COVID-19 Patients Receiving Compassionate Use Leronlimab. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa1583.
   Web of Science ®Google Scholar
• Patterson BK, Seethamraju H, Dhody K, et al. CCR5 Inhibition in Critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14. Int J Infect Dis. 2021;103:25–32. doi:10.1016/j.ijid.2020.10.101.33186704
   PubMed Web of Science ®Google Scholar
• Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020;m1849. doi:10.1136/bmj.m1849.32409561
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Dufort EM, Udo T, et al. Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State. JAMA. 2020;323(24):2493. doi:10.1001/jama.2020.863032392282
   PubMed Web of Science ®Google Scholar
• Geleris J, Sun Y, Platt J, et al. Observational study of hydroxychloroquine in hospitalized patients with COVID-19. N Engl J Med. 2020;382(25):2411–2418. doi:10.1056/NEJMoa201241032379955
   PubMed Web of Science ®Google Scholar
• Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19. N Engl J Med. 2020;382(19):1787–1799. doi:10.1056/NEJMoa200128232187464
   PubMed Web of Science ®Google Scholar
• Monari C, Gentile V, Camaioni C, Marino G, Coppola N, Vanvitelli Covid-Group. A focus on the nowadays potential antiviral strategies in early phase of coronavirus disease 2019 (Covid-19): a narrative review. Life (Basel). 2020;10(8):E146. doi:10.3390/life1008014632784922
   PubMed Web of Science ®Google Scholar
• McCreary EK, Angus DC. Efficacy of remdesivir in COVID-19. JAMA. 2020;324(11):1041. doi:10.1001/jama.2020.1633732821934
   PubMed Web of Science ®Google Scholar
• Horby P, Lim WS, Dodd LE, et al. RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19 - preliminary report [published online ahead of print, 2020. N Engl J Med. 2020. doi:10.1056/NEJMoa2021436
   Web of Science ®Google Scholar
• Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P, PLACID Trial Collaborators. Convalescent plasma in the management of moderate covid-19 in adults in India: open label Phase II multicentre randomised controlled trial (PLACID Trial). BMJ. 2020;371. doi:10.1136/bmj.m3939.
   Web of Science ®Google Scholar
• Pathak EB. Convalescent plasma is ineffective for covid-19. BMJ. 2020;371. doi:10.1136/bmj.m4072
   Web of Science ®Google Scholar
• Ronco C, Bagshaw SM, Bellomo R, et al. Extracorporeal blood purification and organ support in the critically ill patient during covid-19 pandemic: expert review and recommendation. Blood Purif. 2020;50(1):17–27. doi:10.1159/00050812532454500
   PubMed Web of Science ®Google Scholar